🇪🇺#SNY #отчетность
Sanofi Q4 22 Earnings
- Business EPS EU1.71 (est EU1.72)
- Sales EU10.73B (est EU11.01B)
- Vaccines Gross Margin 58.9% (est 59%)
- Business Oper Income EU2.72B (est EU2.72B)
- FY Div/Shr EU3.56 (est EU3.51)
- Sees FY Low Single-Digit Business Eps Growth Ex-FX

🇪🇺#SNY #PRVB #mna
Sanofi купит Provention Bio за $2,9 млрд - по $25 за акцию